Men's Health

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

The management of BPH has had an interesting roller coaster ride over the past 25 years with new medicines, minimally invasive surgical therapies, and a host of novel surgical technologies, including lasers and bipolar electrosurgery.

A handheld transurethral therapy that delivers targeted sterile water vapor reduces lower urinary tract symptom severity in patients with BPH with no impact on sexual function.

After accounting for the risk of reclassification, carefully monitored men with favorable-risk prostate cancer who enroll in active surveillance and undergo delayed surgery are no more likely to demonstrate adverse features associated with 15-year prostate cancer-specific mortality than their counterparts who elect immediate curative treatment, say researchers from the Johns Hopkins University Brady Urological Institute, Baltimore.

After a median of 2 years in an active surveillance cohort being followed with multiparametric-magnetic resonance imaging and MRI-transrectal ultrasound fusion-guided biopsy (“targeted biopsy”), rates of biopsy-proven pathologic progression are similar among men with low-risk and intermediate-risk disease, say researchers from the National Institutes of Health.

Among men who are potent and have low-risk prostate cancer, focal cryotherapy appears to deliver similar oncologic control but with much better recovery of erectile function than a whole-gland approach, according to an analysis using data from the Cryo On-Line Data Registry.

Here are the AUA 2015 take-home messages on sexual/dysfunction, presented by Landon Trost, MD.

Two recently published studies significantly contribute to current knowledge regarding testosterone therapy and cardiovascular health, says one expert urologist.

The cost of radiation therapy for prostate cancer in the United States varies substantially, and most of the variation is accounted for by factors that are not related to the patient or tumor, according to the results of a study published online in Journal of Oncology Practice (Aug. 11, 2015).

A newly identified subset of prostate cancer biomarkers could help explain why African-American men are more likely than European-American men to develop and die from prostate cancer.

Middle-aged and older men undergoing testosterone replacement therapy aren’t at increased risk of venous thromboembolism (VTE), the results of a large comparative case-control analysis published online in Mayo Clinic Proceedings (July 15, 2015) suggest.

A new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.

With conflicting data, should docetaxel be used up front in newly diagnosed metastatic disease?

Treatment with metformin plus a statin appears to pay huge dividends in high-risk prostate cancer patients, data from a large study show.

Docetaxel (Taxotere) added to standard hormone therapy extended mean survival by about 10 months, according to a recent large-scale study.

“It is a positive thing, because the technology we’re using now is not really very accurate," one urologist told Urology Times.

In this round-up of new urology products and services, learn about an app that helps moviegoers with OAB, a new mesh for sacrocolpopexy, and device/smartphone app that help women with pelvic floor exercises.

Congress doesn’t appear to like very much President Obama’s FY 2016 budget proposal to eliminate funding for Centers for Disease Control and Prevention activities that are focused on education about prostate cancer screening and treatment, as well as tracking disease incidence and mortality data.

A novel investigational oral testosterone replacement therapy restored and maintained testosterone levels to a eugonadal range in 88% of hypogondal men treated with the agent in a randomized clinical trial.

ARN-509, a novel oral antiandrogen, was safe, well tolerated, and showed promising efficacy in men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC) in a phase II study, reported Neal D. Shore, MD.

Use of testosterone replacement therapy more than tripled between 2003 and 2012 in a population of reproductive-age men, according to a study presented at the AUA annual meeting in New Orleans.

Higher radiation doses don’t confer a survival benefit in men with low-risk prostate cancer, although they do increase survival rates for men with medium- and high-risk cancers, the authors of a new study report.

Despite the strategy’s benefits, many low-risk patients still undergo surgical or radiation treatment, researchers report.

A large, randomized trial provides a head-to-head comparison of late complications involving the two approaches to BPH.

Study findings suggest that high levels of vitamin D could be harmful to the prostate.